Neurocrine Biosciences Inc. has announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA (valbenazine) capsules and AUSTEDO XR (deutetrabenazine). The study utilized positron emission tomography (PET) imaging to assess VMAT2 target occupancy following single doses of either INGREZZA (40 mg or 80 mg) or AUSTEDO XR (24 mg or 48 mg) in eight participants. Results showed that INGREZZA achieved a higher estimated steady-state VMAT2 occupancy at therapeutic doses (83% for 40 mg and 92% for 80 mg) compared to AUSTEDO XR (54% for 24 mg and 70% for 48 mg). These findings were presented at a recent meeting and are relevant to treatment considerations for involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA63689) on January 15, 2026, and is solely responsible for the information contained therein.